PEAK6
ARQT icon

PEAK6’s Arcutis Biotherapeutics ARQT Stock Holding History

PEAK6’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,000
Closed -$140K – 2912
2025
Q2 		$140K Hold
10,000
– – ﹤0.01% 2555
2025
Q1 		$156K Sell
10,000
-10,000
-50% -$141K ﹤0.01% 2506
2024
Q4 		$279K Buy
+20,000
New +$219K ﹤0.01% 2418

Other funds holding ARQT

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PEAK6's ARQT Position: Q3 2025 in Review

PEAK6 sold out of Arcutis Biotherapeutics (ARQT) in Q3 2025, closing a stake of 10,000 shares — an estimated $140K sold.

PEAK6 first reported a position in ARQT in Q4 2024 and held it in 3 quarters. The position peaked at $279K in Q4 2024. 239 funds tracked by Wall St. Rank hold ARQT as of Q3 2025.

  • PEAK6 reported no remaining Arcutis Biotherapeutics position as of Q3 2025 after selling out during the quarter.
  • PEAK6 sold 10,000 Arcutis Biotherapeutics shares in Q3 2025, an estimated $140K.
  • PEAK6 first reported a position in Arcutis Biotherapeutics in Q4 2024 and held it in 3 quarters.
  • PEAK6's Arcutis Biotherapeutics position peaked at $279K in Q4 2024.
  • 239 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q3 2025.

Based on PEAK6's 13F filing for Q3 2025, filed 14 Nov 2025.